Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 23

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
Adjustments to reconcile net loss to net cash used in operating activities:Change in carrying value of right-of-use asset19 19 Stock-based compensation expense1,550 2,229 Stock issued in exchange for services- 25 Changes in operating assets and liabilities, net:Accrued interest on marketable debt securities- (134)Prepaid expenses, other current assets, and other assets(344)96 Accounts payable, accrued expenses and other liabilities498 (1,700)Net cash used in operating activities(6,832)(12,552)Cash flows from investing activities:Purchase of marketable debt securities- (3,056)Redemption of marketable debt securities- 9,410 Net cash provided by investing activities- 6,354 Cash flows from financing activities:Proceeds from public offerings4,652 - Issuance costs related to public offerings(933)- Proceeds from ATM offerings7,884 232 Issuance costs related to ATM offerings(318)(82)Proceeds from common stock issuances24 - Proceeds from exercise of warrants and options- 274 Net cash provided by financing activities11,309 424 Net increase (decrease) in cash and cash equivalents4,477 (5,774)Cash and cash equivalents at beginning of period2,590 8,556 Cash and cash equivalents at end of period$7,067 $2,782 Supplemental disclosure of non-cash financing activities:Common stock issued in exchange for services$- $51 

The accompanying notes are an integral part of these condensed financial statements.

4

INTENSITY THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 1.    Description of Business

Intensity Therapeutics, Inc. (the “Company”) is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRxSM technology platform has identified a lead drug, INT230-6.  The Company is based in Connecticut and was incorporated in Delaware in December 2012.  The Company has completed two clinical studies and enrolled over 200 patients using INT230-6 in a Phase 1/2 dose escalation study in metastatic cancers including sarcomas, and a Phase 2 randomized control clinical trial in locally advanced breast cancer in women without undergoing chemotherapy prior to their surgery.